(115 days)
Terragene® Bionova® BT20 Biological Indicator is a Self-Contained Biological Indicator (SCBI) intended for routine monitoring of the efficacy of the following steam sterilization processes:
• Gravity-displacement Steam Sterilization Cycles
- 121 °C, 30 minutes
- 132 °C, 25 minutes
- 132 °C, 15 minutes
- 132 °C, 10 minutes
- 134/135 °C, 10 minutes
• Vacuum-assisted Steam Sterilization Cycles
- 121 °C, 20 minutes
- 132 °C, 4 minutes
- 134/135 °C, 3 minutes
Terragene® Bionova® BT20 provides a final result after a 24 hour incubation at 60 ± 2 °C.
Terragene® Bionova® BT20 Biological Indicators are single-use Self-Contained Biological Indicators (SCBIs) that consist of a polypropylene tube, a filter paper spore carrier inoculated with a minimum of 10⁶ viable Geobacillus stearothermophilus ATCC® 7953 spores and a glass ampoule containing purple culture medium, enclosed with a plastic colored cap and a barrier permeable to steam. The culture medium contains a pH indicator that changes color upon acidification by the metabolism of living spores. On each BT20 Biological Indicator there is a propylene label printed with a chemical process indicator that changes from pink to brown when exposed to steam.
Final results: 24-hour readout after incubation at 60 °C. If the sterilization process was successful, culture medium will remain purple. If sterilization was not successful, culture medium will turn to yellow during incubation, thus indicating the presence of live G. stearothermophilus spores.
This document describes the acceptance criteria and the study proving the Terragene® Bionova® BT20 Biological Indicator meets these criteria.
It's important to note that this device is a Biological Indicator for sterilization, not an Artificial Intelligence (AI) or medical imaging device. Therefore, some of the requested information (like multi-reader multi-case studies, ground truth establishment for AI training, etc.) is not applicable. The information provided focuses on the rigorous testing required for biological indicators to demonstrate their efficacy in monitoring sterilization processes.
1. A table of acceptance criteria and the reported device performance
The following table summarizes the acceptance criteria and the "Results" कॉलम में "Passed" यह बताता है कि डिवाइस ने उन सभी मापदंडों को सफलतापूर्वक पूरा किया है।
| Test Performed | Purpose | Acceptance Criteria | Reported Device Performance |
|---|---|---|---|
| Viable Spore Population Assay | Demonstrate that the product meets specifications for spore population. | - 50 to 300% of manufacturer's nominal population (ISO 11138-1:2017).- ≥ 10⁵ CFU/BI unit (FDA Guidance, ISO 11138-3:2017). | Passed |
| Resistance Characteristics Study | Evaluate the resistance characteristics (D-value, Z-value, Survival Time, Kill Time). | - D-value₁₂₁°C: ≥ 1.5 minutes- D-value₁₃₂°C: ≥ 10 seconds- D-value₁₃₅°C: ≥ 8 seconds- Z-value: ≥ 10°C- Minimum Expected Survival Time₁₂₁°C: ≥ 5 minutes- Minimum Expected Survival Time₁₃₂°C: ≥ 1 minute- Minimum Expected Survival Time₁₃₄/₁₃₅°C: ≥ 40 seconds- No negative results at Minimum Expected Survival Time.- No positive results at Maximum Expected Kill Time. | Passed |
| Recovery Protocols: Recovery Medium Test | Test suitability of the culture medium. | - All inoculated samples show positive result (color change to yellow) after 7-day incubation at 60°C.- Negative controls (uninoculated) show negative result (medium remains purple) after 7-day incubation at 60°C. | Passed |
| Carrier and Primary Packaging Materials Evaluation | Evaluate effect of materials on spore viability and suitability. | - No "no growth" in exposed carrier samples.- No "no growth" in unexposed carrier samples.<br;- No "no growth" in exposed primary packaging samples.- No "no growth" in unexposed primary packaging samples.- Valid growth medium controls. | Passed |
| Reduced Incubation Time (RIT) Test | Validate the 24-hour Reduced Incubation Time. | 24-hour RIT sensitivity ≥ 97% for each partial sterilization cycle for all three batches. | Passed |
| Holding Time Assessment | Validate maximum 7-day holding time between exposure and incubation. | - D-value within ± 20% following holding time.- All inoculated samples positive after 7 days incubation at 60°C.- Negative controls negative under same conditions. | Passed |
| Shelf Life Study (Biological Indicator) | Demonstrate stability of specifications throughout labeled shelf life. | - Spore population: 50% to 300% of initial nominal value.- D-Value: within ± 20% of initial value.- Product performance: Negative result for successful sterilization (purple), Positive result for unsuccessful/control (yellow) after 24-hour incubation at 60°C. | Passed |
| Performance Study for Bionova® BT20 Biological Indicator | Verify performance in claimed cycles. | The Biological Indicator should perform as intended in claimed cycles. | Passed |
| Pass/Fail Criteria for Chemical Indicator Label | Validate performance of chemical process indicator. | - Pass conditions: CI turns brown.- Fail conditions: CI does not reach endpoint.- Dry heat: No color change or significantly different from endpoint. | Passed |
| Endpoint Stability for Chemical Indicator Label | Demonstrate stability of endpoint reaction for CI. | Stability of endpoint reaction demonstrated at end of shelf life and for at least 6 months. | Passed |
| Shelf Life Study for Chemical Indicator Label | Provide real-time data for CI endpoint response. | Stability of endpoint reaction demonstrated throughout shelf life when stored under labeled conditions. | Passed |
| Biocompatibility for Chemical Indicator Label | Demonstrate CI label does not offset or transfer. | CI should not release any substance or bleed when in contact with substrate and subject to sterilization. | Passed |
2. Sample size used for the test set and the data provenance
The document does not explicitly state the specific numerical sample sizes for each test in terms of "number of devices tested." However, it consistently refers to testing "three batches analyzed" for critical tests like Viable Spore Population Assay and Reduced Incubation Time (RIT) Test. This suggests a minimum sample size of three batches of the biological indicators for key performance evaluations.
- Data Provenance: The studies were non-clinical performance tests conducted by the manufacturer, Terragene S.A., based in Alvear, Santa Fe, Argentina. The studies are by nature prospective, as they involve manufacturing the device and then subjecting it to controlled tests to demonstrate performance against established standards.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not applicable as the device is a biological indicator for sterilization monitoring, not an AI or medical imaging device that relies on expert human interpretation for ground truth. The "ground truth" for a biological indicator is defined by the objective outcome of sterilization cycles (e.g., whether spores are killed or grow) and the established scientific standards for spore population, resistance, and growth media. These are measured objectively in a laboratory setting.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This information is not applicable. Adjudication methods like 2+1 or 3+1 are typically used in clinical studies or AI evaluations where human experts are making subjective assessments that need to be reconciled. For a biological indicator, the results are objective (e.g., color change, spore growth/no growth, D-value calculation) based on laboratory protocols defined by ISO standards and FDA guidance.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not applicable. This is a biological indicator designed to monitor sterilization, not an AI-assisted diagnostic tool. Therefore, MRMC studies involving human readers and AI assistance are irrelevant to this device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This information is not applicable. The device is a physical biological indicator, not an algorithm. Its performance is evaluated in a standalone manner as a biological entity in controlled sterilization and incubation environments, without human intervention during the "reading" phase (i.e., the color change is observed visually or automatically after incubation, it's not a human performing a complex interpretation). The "algorithm" in this context is the biological response of the spores.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The ground truth for a biological indicator is primarily established through:
- Microbiological Viability: The presence or absence of viable Geobacillus stearothermophilus spores after exposure to sterilization conditions, confirmed by observed growth or no growth in a suitable culture medium.
- Physical Parameters: Precisely controlled and measured physical parameters of the sterilization cycles (temperature, time, pressure) that are known to either kill or allow survival of the specific spore population.
- Referenced Standards: The "ground truth" is also defined by the detailed specifications and methodologies outlined in international standards such as ISO 11138-1:2017, ISO 11138-3:2017, and ISO 11138-8:2021, and FDA Guidance documents for biological indicators. These standards define the acceptable D-values, spore populations, survival times, and kill times under specified conditions.
Essentially, the ground truth is based on established scientific and microbiological principles and standardized test methodologies rather than subjective expert consensus or pathology.
8. The sample size for the training set
This information is not applicable as the device is a biological indicator and does not involve AI or machine learning that requires a "training set" of data.
9. How the ground truth for the training set was established
This information is not applicable for the same reason as above.
FDA 510(k) Clearance Letter - Terragene® Bionova® BT20 Biological Indicator
Page 1
August 4, 2025
Terragene
Hernando Carrizo
Quality and Process Manager
Ruta Nacional N° 9, km 280,
Parque Industrial Micropi
Alvear, Santa Fe 2130
Argentina
Re: K251122
Trade/Device Name: Terragene® Bionova® BT20 Biological Indicator
Regulation Number: 21 CFR 880.2800
Regulation Name: Sterilization Process Indicator
Regulatory Class: Class II
Product Code: FRC
Dated: April 9, 2025
Received: April 11, 2025
Dear Hernando Carrizo:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Page 2
K251122 - Hernando Carrizo Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
Page 3
K251122 - Hernando Carrizo Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Stephen A. Anisko -S
Digitally signed by Stephen A. Anisko -S
Date: 2025.08.04 17:22:46 -04'00'
Stephen Anisko
Acting Assistant Director
DHT4C: Division of Infection Control Devices
OHT4: Office of Surgical and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
Indications for Use
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
510(k) Number (if known)
K251122
Device Name
Terragene® Bionova® BT20 Biological Indicator
Indications for Use (Describe)
Terragene® Bionova® BT20 Biological Indicator is a Self-Contained Biological Indicator (SCBI) intended for routine monitoring of the efficacy of the following steam sterilization processes:
• Gravity-displacement Steam Sterilization Cycles
- 121 °C, 30 minutes
- 132 °C, 25 minutes
- 132 °C, 15 minutes
- 132 °C, 10 minutes
- 134/135 °C, 10 minutes
• Vacuum-assisted Steam Sterilization Cycles
- 121 °C, 20 minutes
- 132 °C, 4 minutes
- 134/135 °C, 3 minutes
Terragene® Bionova® BT20 provides a final result after a 24 hour incubation at 60 ± 2 °C.
Type of Use (Select one or both, as applicable)
☐ Prescription Use (Part 21 CFR 801 Subpart D) ☒ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/23) Page 1 of 1
Page 5
510(k) Summary for Terragene® Bionova® BT20 Biological Indicator K251122
Sponsor Information:
Terragene S.A.
Ruta Nacional N° 9, km 280
Parque Industrial Micropi, Alvear
Santa Fe, 2130, Argentina
Contact: Mr. Hernando Carrizo
Quality and Process Manager
Phone Number: +5493415587007
Email: asuntos.regulatorios@terragene.com.ar
Date of Summary: 24 July 2025
1. Device Name and Classification:
Common or Usual Name: Biological Indicator (BI)
Proprietary Name: Terragene® Bionova® BT20 Biological Indicator
Classification Name: Indicator, Biological Sterilization Process
Device Classification: Class II, 21 CFR 880.2800
Product Code: FRC
K251122 Page 1 of 9
Page 6
K251122 Page 2 of 9
2. Predicate Device:
Terragene® Bionova® BT220 SCBI, K163646.
3. Description of Device:
Terragene® Bionova® BT20 Biological Indicators are single-use Self-Contained Biological Indicators (SCBIs) that consist of a polypropylene tube, a filter paper spore carrier inoculated with a minimum of 10⁶ viable Geobacillus stearothermophilus ATCC® 7953 spores and a glass ampoule containing purple culture medium, enclosed with a plastic colored cap and a barrier permeable to steam. The culture medium contains a pH indicator that changes color upon acidification by the metabolism of living spores. On each BT20 Biological Indicator there is a propylene label printed with a chemical process indicator that changes from pink to brown when exposed to steam.
Final results: 24-hour readout after incubation at 60 °C. If the sterilization process was successful, culture medium will remain purple. If sterilization was not successful, culture medium will turn to yellow during incubation, thus indicating the presence of live G. stearothermophilus spores.
4. Indications for Use
Terragene® Bionova® BT20 Biological Indicator is a Self-Contained Biological Indicator (SCBI) intended for routine monitoring of the efficacy of the following steam sterilization processes:
• Gravity-displacement Steam Sterilization Cycles
- 121 °C, 30 minutes
- 132 °C, 25 minutes
- 132 °C, 15 minutes
- 132 °C, 10 minutes
- 134/135 °C, 10 minutes
• Vacuum-assisted Steam Sterilization Cycles
- 121 °C, 20 minutes
- 132 °C, 4 minutes
- 134/135 °C, 3 minutes
Terragene® Bionova® BT20 provides a final result after a 24-hour incubation at 60 ± 2 °C.
Page 7
K251122 Page 3 of 9
5. Comparison of Technological Characteristics with the Predicate Device
The similarities and differences between the subject biological indicator and the predicate device are illustrated in the Device Technological Characteristics Comparison Table (Table 1).
Table 1: Device Technological Characteristics Comparison Table
| Feature | Subject Device: (K251122) | Predicate Device: (K163646) |
|---|---|---|
| Name | Terragene® Bionova® BT20 Biological Indicator | Terragene® Bionova® SCBI BT220 |
| Product Code | FRC | Same |
| Regulation | 880.2800 | Same |
| Class | II | Same |
| Intended Use | Single Use sterilization process indicator for Steam at 121°C, 132°C, 134° and 135°C | Similar. Single Use sterilization process indicator for Steam at 121°C, 132°C, and 135°C |
| Indications for Use | Terragene® Bionova® BT20 Biological Indicator is a Self-Contained Biological Indicator (SCBI) intended for routine monitoring of the efficacy of the following steam sterilization processes:• Gravity-displacement Steam Sterilization Cycles- 121 °C, 30 minutes- 132 °C, 25 minutes- 132 °C, 15 minutes- 132 °C, 10 minutes- 134/135 °C, 10 minutes• Vacuum-assisted Steam Sterilization Cycles- 121 °C, 20 minutes- 132 °C, 4 minutes- 134/135 °C, 3 minutesTerragene® Bionova® BT20 provides a final result after a 24-hour incubation at 60 ± 2 °C. | Similar. Terragene® Bionova® SCBI (BT220) is a self-contained biological indicator inoculated with viable Geobacillus stearothermophilus bacterial spores and is intended for monitoring the efficacy of Steam sterilization processes.• Gravity-displacement Steam Sterilization Cycles- 121 °C, 30 minutes- 132 °C, 25 minutes- 132 °C, 15 minutes- 135 °C, 10 minutes• Vacuum-assisted Steam Sterilization Cycles- 132 °C, 4 minutes- 135 °C, 3 minutesFluorescence Read Time: 3 hours.pH Color Change: 48 hours. |
| Construction | Vial, brown cap, paper filter of the cap, paper spore carrier, glass ampoule with growth media including a pH indicator | Similar. Vial, brown cap, paper filter of the cap, paper spore carrier, glass ampoule with growth media including a pH indicator and a non-fluorescent substrate, 4-methylumbelliferyl-⍺-D-glucoside (MUG) |
Page 8
K251122 Page 4 of 9
| Feature | Subject Device: (K251122) | Predicate Device: (K163646) |
|---|---|---|
| Principle of Operation | The device consists of a known number of microorganisms, of a known resistance to the sterilization method and a glass ampoule containing culture medium. The medium contains a pH indicator that changes color upon acidification by the metabolic activity of living spores. Subsequent growth or failure to grow of the microorganisms under suitable conditions indicates the adequacy of sterilization. | Similar. In addition to the visual color change, BT220 also features a 3-hour fluorescence readout based on the α-glucosidase activity, an enzyme associated to Geobacillus stearothermophilus spores. The presence of fluorescence upon incubation in the Auto-reader indicates a sterilization process failure. |
| Type of BI | Self-Contained Biological Indicator | Same |
| Organism (Spore, Species, Strain) | Geobacillus stearothermophilus ATCC® 7953 | Same |
| Viable spore population | ≥10⁶ spores per vial | Same |
| Resistance Characteristics | D-value₁₂₁ °C: ≥ 1.5 minutesD-value₁₃₂ °C: ≥ 10 secondsD-value₁₃₅ °C: ≥ 8 seconds | Same |
| Carrier material | Paper | Same |
| Culture medium color change | If sterilization process is not successful, indicator medium will turn yellow after incubation.If sterilization process was successful, indicator medium will remain purple after incubation. | Same |
| Chemical Indicator (SCBI Label) | Type 1 process indicator per ISO 11140-1 that changes color to indicate exposure to steam; changes from pink towards brown. | Same. Identical chemical process indicator ink, location, substrate (label), and visual interpretation. |
| Biological Indicator Incubation Temperature | 60 ± 2 ºC | Same |
| Reduced Incubation Time | Visual color change following 24-hour incubation | Visual color change following 48-hour incubation |
| Sterile | Non-sterile | Same |
| Shelf Life | 2 years | Same |
Both subject and predicate devices have similar intended use and indications for use. This submission introduces a reduced incubation that is supported by performance testing. They are Self-Contained Biological Indicators (SCBIs) made up with the same organism. Subject and predicate devices have same specifications for spore population, resistance characteristics and temperature of incubation. Subject and predicate devices have the same shelf-life. In addition, the predicate device has a chemical indicator printed on the label, which is identical in material, color transition, and function to the CI on the subject device. The subject and predicate devices operate on the same principle. The only difference is that the predicate device can also monitor the sterilization process efficacy via fluorescence readout.
Page 9
K251122 Page 5 of 9
6. Nonclinical Comparison to the Predicate Device
The differences between the submission and predicate devices have been evaluated through performance tests for the Terragene® Bionova® BT20 Biological Indicator.
Performance of the Terragene® Bionova® BT20 Biological Indicator was verified through the following tests:
| Test Performed | Applicable Standards | Purpose | Acceptance Criteria | Results |
|---|---|---|---|---|
| Viable Spore Population Assay | ISO 11138-1:2017, ISO 11138-3:2017, and the FDA Guidance for Industry and FDA Staff, Biological Indicator (BI) Premarket Notification [510(k)] Submissions, October 4, 2007. | Demonstrate that the product Bionova® BT20 meets specifications for spore population (≥10⁵ CFU/BI unit). | Bionova® BT20 should meet specifications for spore population (50 to 300 % of the manufacturer's stated nominal population) according to ISO 11138-1:2017 standard, for the three batches analyzed. Bionova® BT20 should meet specifications for spore population (≥ 10⁵ CFU/BI unit) according to the FDA Guidance for Industry and FDA Staff "Biological Indicator (BI) Premarket Notification [510(k)] Submissions", and ISO 11138-3:2017 standard, for the three batches analyzed. | Passed |
| Resistance Characteristics Study | ISO 11138-1:2017, ISO 11138-3:2017, and the FDA Guidance for Industry and FDA Staff, Biological Indicator (BI) Premarket Notification [510(k)] Submissions, October 4, 2007. | Evaluate the resistance characteristics of Bionova® BT20 Biological Indicator. To achieve this aim, four parameters were determined: D-value; Z-value; Survival Time; Kill Time. | D-value should not be lower than 1.5 minutes at 121 °C.D-value should not be lower than 10 seconds at 132 °C.D-value should not be lower than 8 seconds at 134 or 135 °C.Z-value should not be lower than 10 °C.Minimum Expected Survival Time should not be lower than 5 minutes at 121 °C.Minimum Expected Survival Time should not be lower than 1 minute at 132 °C.Minimum Expected Survival Time should not be lower than 40 seconds at 134 or 135 °CNo negative results should be obtained for Bionova® BT20 SCBIs exposed to the Minimum Expected Survival Time.No positive results should be obtained for Bionova® BT20 SCBIs exposed to the Maximum Expected Kill Time. | Passed |
| Recovery Protocols: Recovery Medium Test | ISO 11138-1:2017 standard. | Test suitability of the culture medium used in the build-up of Bionova® BT20 Biological Indicator. | All the inoculated samples should show a positive result (culture medium color change from purple to yellow) after a 7-day incubation at 60 °C.Negative controls (uninoculated samples) should show a negative result (culture medium remaining purple) after a 7-day incubation at 60 °C. | Passed |
Page 10
K251122 Page 6 of 9
| Test Performed | Applicable Standards | Purpose | Acceptance Criteria | Results |
|---|---|---|---|---|
| Carrier and Primary Packaging Materials Evaluation | ISO 11138-1:2017 standard. | Evaluate the effect of carrier and primary packaging materials of Bionova® BT20 Biological Indicator to confirm that they do not retain or release inhibitory substances and demonstrate their suitability for the intended sterilizations process. | If "no growth" occurs in one or more of the growth medium controls, the test procedure shall not be regarded as valid.If "growth" occurs in one or more of the negative growth controls, the test procedure shall not be regarded as valid.If "no growth" occurs in one or more of the six exposed carrier samples, the carrier shall not be regarded as suitable for the manufacture of inoculated carriers or BIs.If "no growth" occurs in one or more of the three unexposed carrier samples, the carrier material shall not be regarded as suitable for the manufacture of inoculated carriers or biological indicators.If "no growth" occurs in one or more of the six exposed primary packaging samples, the primary packaging shall not be regarded as suitable for the manufacture of biological indicators.If "no growth" occurs in one or more of the three unexposed primary packaging samples, the primary packaging material shall not be regarded as suitable for the manufacture of biological indicators. | Passed |
| Reduced Incubation Time (RIT) Test | ISO 11138-1:2017, ISO 11138-8:2021 and the FDA Guidance for Industry and FDA Staff, Biological Indicator (BI) Premarket Notification [510(k)] Submissions, October 4, 2007. | Validate the 24-hour Reduced Incubation Time for Bionova® BT20 Biological Indicator. | The 24-hour Reduced Incubation Time sensitivity should be greater than or equal to 97 % for each partial sterilization cycle for the three Bionova® BT20 Biological Indicators batches. | Passed |
| Holding Time Assessment | FDA Guidance for Industry and FDA Staff, Biological Indicator (BI) Premarket Notification [510(k)] Submissions, October 4, 2007. | Validate a maximum 7-day holding time between exposure and incubation, during which resistance parameters and spore recovery should remain stable. | Bionova® BT20 Biological Indicators D-value should remain within ± 20 % following the specified holding time.All inoculated samples should show a positive result after 7 days of incubation at 60 °C. Negative controls should show a negative result under the same conditions. | Passed |
Page 11
K251122 Page 7 of 9
| Test Performed | Applicable Standards | Purpose | Acceptance Criteria | Results |
|---|---|---|---|---|
| Shelf Life Study | ISO 11138-1:2017 standard. | Demonstrate that the specifications of Bionova® BT20 are maintained throughout the labeled shelf life of the product. To achieve this aim, three characteristics should be evaluated:▪ Spore population stability.▪ D-value stability.▪ Product performance. | Spore population stability studyIn accordance with requirements described in ISO 11138-1:2017, spore population should be accepted when, during the entire shelf-life of the SCBI, it is within the range of 50 to 300 % of the value initially stated by the manufacturer.D-Value stability studyAccording to ISO 11138-1:2017, the D-value shall be acceptable when, during the entire shelf-life of the SCBI, it is within ± 20 % of the value stated by the manufacturer at the time of production.Product performance studyPerformance of the BI shall not be altered during its shelf-life. The BI shall meet the following parameters:A BI exposed to a successful sterilization process should test negative (culture medium should remain purple) after a 24-hour incubation at 60 °C.A BI used as positive control (not exposed to a sterilization process) or a BI exposed to a non-satisfactory sterilization process, should test positive (culture medium should turn to yellow) after a 24-hour incubation at 60 °C. | Passed |
| Performance Study for Bionova® BT20 Biological Indicator | FDA Guidance for Industry and FDA Staff, Biological Indicator (BI) Premarket Notification [510(k)] Submissions, October 4, 2007 and the FDA Guidance for Industry and FDA Staff on Premarket Notification [510(k)] Submissions for Chemical Indicators, December 19, 2003. | Verify the performance of the device in claimed cycles. | The Biological Indicator should perform as intended in claimed cycles. | Passed |
Page 12
K251122 Page 8 of 9
| Test Performed | Applicable Standards | Purpose | Acceptance Criteria | Results |
|---|---|---|---|---|
| Pass/Fail Criteria for Bionova® BT20 chemical indicator label | ISO 11140-1:2014 and the FDA Guidance for Industry and FDA Staff on Premarket Notification [510(k)] Submissions for Chemical Indicators, December 19, 2003. | Validate the performance of chemical process indicator on Bionova® BT20 label in resistometer | After exposure to the indicated pass conditions, the chemical indicator should reach its endpoint by turning brown. After exposure to fail conditions, chemical indicator should not reach its endpoint. After exposure to dry heat, no color change or change significantly different from the endpoint condition is expected. | Passed |
| Validate the performance of chemical process indicator on Bionova® BT20 label in actual sterilizer | After exposure to pass conditions, the chemical indicator should reach its endpoint by turning brown. After exposure to fail conditions, chemical indicator should not reach its endpoint. | Passed | ||
| Endpoint Stability for Bionova® BT20 chemical indicator label | ISO 11140-1:2014 and the FDA Guidance for Industry and FDA Staff on Premarket Notification [510(k)] Submissions for Chemical Indicators, December 19, 2003. | Demonstrate the stability of the endpoint reaction of the Chemical Indicator printed on Bionova® BT20 Biological Indicator label at the end of their shelf life and for a period of at least 6 months. | Stability of endpoint reaction of Chemical Indicator printed on Bionova® BT20 Biological Indicator label should be demonstrated at the end of its shelf life and for a period of 6 months. | Passed |
| Shelf Life Study for Bionova® BT20 chemical indicator label | FDA Guidance for Industry and FDA Staff on Premarket Notification [510(k)] Submissions for Chemical Indicators, December 19, 2003. | Provide real-time data to demonstrate that the endpoint response specification of the chemical indicator printed on the Bionova® BT20 Biological Indicator label is maintained over 24 months. | The stability of the endpoint reaction for the chemical indicator printed on the Bionova® BT20 Biological Indicator label should be demonstrated throughout its shelf life when stored under the labeled storage conditions. | Passed |
| Biocompatibility for Bionova® BT20 chemical indicator label | ISO 11140-1:2014 and the FDA Guidance for Industry and FDA Staff on Premarket Notification [510(k)] Submissions for Chemical Indicators, December 19, 2003. | Demonstrate that Bionova® BT20 Chemical Indicators label do not offset or transfer when is in contact with the same substrate from which they were manufactured. | The chemical indicator printed on the Bionova® BT20 Biological Indicator should not release any substance or bleed when they come in contact with their substrate and are subject to the sterilization process. | Passed |
Page 13
K251122 Page 9 of 9
7. Clinical Comparison to the Predicate Device
Clinical testing was not required for this submission.
8. Conclusion
Based on the intended use, technological characteristics, and non-clinical performance data, the subject device, the Terragene® Bionova® BT20 Biological Indicator, is as safe, as effective, and performs as well as the legally marketed predicate device, the Terragene® Bionova® BT220 SCBI cleared per K163646, Class II (21 CFR 880.2800), product code FRC.
§ 880.2800 Sterilization process indicator.
(a)
Biological sterilization process indicator —(1)Identification. A biological sterilization process indicator is a device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor adequacy of sterilization. The device consists of a known number of microorganisms, of known resistance to the mode of sterilization, in or on a carrier and enclosed in a protective package. Subsequent growth or failure of the microorganisms to grow under suitable conditions indicates the adequacy of sterilization.(2)
Classification. Class II (performance standards).(b)
Physical/chemical sterilization process indicator —(1)Identification. A physical/chemical sterilization process indicator is a device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor one or more parameters of the sterilization process. The adequacy of the sterilization conditions as measured by these parameters is indicated by a visible change in the device.(2)
Classification. Class II (performance standards).